Shopping Cart
Remove All
Your shopping cart is currently empty
Mirikizumab (Synonyms: LY3074828, LY 3074828)
Catalog No. T77088 Copy Product Info
🥰Excellent
Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis.
Mirikizumab
Copy Product Info🥰Excellent
Catalog No. T77088
Synonyms LY3074828, LY 3074828
Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis.
Mirikizumab
Cas No. 1884201-71-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $562 | In Stock | In Stock | |
| 10 mg | $893 | - | In Stock | |
| 25 mg | $1,320 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.41% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Mirikizumab (LY3074828) is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), modulating immune response by inhibiting IL-23 binding to IL-23R, used in studies of ulcerative colitis. |
| In vitro | Mirikizumab binds IL-23 in humans and monkeys with high affinity, with Kd values of 21 pM and 55 pM, respectively. [1] |
| In vivo | Mirikizumab (4.4 pm-800 nM, 48 h) completely neutralizes IL-17A induced by human and cynocytic monkey IL-23 in mouse spleen cells with IC50 of 82 pM and 120 pM, respectively. [1] |
| Synonyms | LY3074828, LY 3074828 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-23 alpha Protein (His) (TMPY-00406) at 1 μg/mL (100 μL/well) can bind Mirikizumab. The EC50 is 6.30 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-23 |
| Molecular Weight | 144.26 kDa |
| Cas No. | 1884201-71-1 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Mirikizumab | purchase Mirikizumab | Mirikizumab cost | order Mirikizumab | Mirikizumab in vivo | Mirikizumab in vitro | Mirikizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.